RxDoctor Payments Data

James Needell, MD

Internal Medicine · Lincolnton, NCNPI 1417988825

Payments from drug & device makers

$11,180in general payments, 2019–2025

Across 176 payments — averaging $63.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$6K
  • Novo Nordisk AS$2K
  • Johnson & Johnson$606
  • Lilly USA, LLC$340
  • Amarin Pharma, Inc.$253
  • AstraZeneca$239
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$2,961100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,180 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,331
Medicare patients
98
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$47,741
MounjaroTirzepatide40$47,269
JardianceEmpagliflozin45$39,777
XareltoRivaroxaban70$26,220
TrulicityDulaglutide45$25,446
JanuviaSitagliptin Phosphate26$17,492
FarxigaDapagliflozin Propanediol11$7,971
TrintellixVortioxetine Hydrobromide25$6,161
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,676
Rivastigmine39$2,059
Propranolol Hcl40$1,816
Humalog Kwikpen U-100Insulin Lispro12$1,508
Duloxetine Hcl50$1,379
Quetiapine Fumarate54$1,336
Amlodipine Besylate176$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$340$72,71585 claims
PfizerEliquis$69$47,74195 claims
Boehringer IngelheimJardiance$130$39,77745 claims
Johnson & JohnsonXarelto$606$26,22070 claims
MerckJanuvia$40$17,49226 claims
AstraZenecaFarxiga$239$7,97111 claims
AbbVieSynthroid$98$1,03911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Lincolnton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →